

COVERAGE EXCEPTION PRESCRIBER FAX FORM

Only the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for preauthorization consideration. For formulary information please visit www.myprime.com.

What is the priority level of this request?

- Standard
- Date of service (if applicable): _____
- Urgent (NOTE: Urgent is defined as when the prescriber believes that waiting for a standard review could seriously harm the patient's life, health, or ability to regain maximum function.)

PATIENT AND INSURANCE INFORMATION

Today's Date: _____

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
Patient Address:		City, State, Zip:	
Member ID Number:		Group Number:	
		Patient Telephone:	

PRESCRIBER/CLINIC INFORMATION

Prescriber Name:	Prescriber NPI#:	Specialty:	Contact Name:
Clinic Name:		Clinic Address:	
City, State, Zip:		Phone #:	Secure Fax #:

RENDERING/SERVICING PRESCRIBER INFORMATION (IF APPLICABLE)

Prescriber Name:	Prescriber NPI#:	Specialty:	Contact Name:
Clinic Name:		Clinic Address:	
City, State, Zip:		Phone #:	Secure Fax #:

PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST

Patient's Diagnosis (ICD code and description):	
Patient's height:	Patient's weight:
Medication Requested:	Strength:
Dosing Schedule:	Quantity per Month:

For all requests:

1. Is the patient currently treated with the requested agent? Yes No
 If yes, is the patient at risk if therapy is changed? Yes No
 If yes, please explain risk: _____
2. Please list all reasons for selecting the requested medication, strength, dosing schedule, and quantity over alternatives (e.g., contraindications, allergies, history of adverse drug reactions to alternatives, lower dose has been tried, information supporting dose over FDA). _____
3. Please list any other medications the patient will use in combination with the requested medication for treatment of this diagnosis. _____
4. Is the requested agent medically necessary? Yes No
 If yes, please provide supporting information: _____

Please continue to the next page.

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
-----------------------	-------	----	-------------------

5. Please list all medications the patient has previously tried and failed for treatment of this diagnosis. Please specify if the patient has tried brand-name products, generic products or over-the-counter products.

_____	Date(s): _____	_____	Date(s): _____
_____	Date(s): _____	_____	Date(s): _____
_____	Date(s): _____	_____	Date(s): _____

6. Please provide information indicating the cause of the patient's failure to any previously tried treatments for this diagnosis. ___

For Aspirin Therapy:

7. Is the patient pregnant, at high risk of preeclampsia, and using the requested agent after 12 weeks gestation? Yes No

For Bowel Prep Therapy:

8. Will the requested agent be used for the preparation of colorectal cancer screening using fecal occult blood testing, sigmoidoscopy, or colonoscopy? Yes No

For Breast Cancer Primary Prevention Therapy:

9. Is the requested agent being requested for the primary prevention of breast cancer? Yes No

10. Is the patient female? Yes No

If no, is the requested agent medically appropriate for the patient's sex? Yes No

If yes, please explain: _____

For Contraceptive Agents:

11. Is the requested agent being used for contraception? Yes No

12. Is the patient female? Yes No

If no, is the requested agent medically appropriate for the patient's sex? Yes No

If yes, please explain: _____

For Folic Acid Therapy:

13. Is the requested agent being used to support pregnancy? Yes No

14. Is the patient female? Yes No

If no, is the requested agent medically appropriate for the patient's sex? Yes No

If yes, please explain: _____

For HIV Infection PrEP Therapy:

15. Is the requested agent being used for PrEP? Yes No

16. Is the requested agent medically necessary? Yes No

If yes, please explain: _____

17. Is the requested PrEP agent any of the following: tenofovir disoproxil fumarate and emtricitabine combination ingredient agent, tenofovir alafenamide and emtricitabine combination ingredient agent, or cabotegravir?... Yes No

18. Does the patient have an increased risk for HIV infection? Yes No

19. Has the patient recently tested negative for HIV? Yes No

Please continue to the next page.

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
-----------------------	-------	----	-------------------

For Infant Eye Ointment Therapy:

20. Is the requested agent for the prevention of gonococcal ophthalmia neonatorum? Yes No

For Iron Supplements Therapy:

21. Is the patient at increased risk of iron deficiency anemia?..... Yes No

For Statin Therapy:

22. Is the requested agent for use in the primary prevention of cardiovascular disease (CVD)? Yes No

23. Does the patient have any of the following CVD risk factors? Check all that apply.

- Dyslipidemia
- Hypertension
- Diabetes
- Smoking

24. Does the patient have a calculated 10-year risk of a cardiovascular event of 10% or greater based on calculations from the ACA/AHA ASCVD Risk Estimator (<https://tools.acc.org/ASCVD-Risk-Estimator/>)?..... Yes No

For Tobacco Cessation Therapy:

25. Is the patient a non-pregnant adult? Yes No

26. Has the patient received 180 or more day supply of the requested tobacco cessation agent type (e.g., NRT, bupropion, varenicline) in the past 365 days? Yes No

If yes, is the patient currently being treated with the requested tobacco cessation agent type (e.g., NRT, bupropion, varenicline) and is expected to be successful on this course of therapy? Yes No

If yes, please explain: _____

If no, is there support for the anticipated success of repeating therapy with the requested tobacco cessation agent type (e.g., NRT, bupropion, varenicline)? Yes No

If yes, please provide supporting information: _____

For Vaccine Therapy:

27. Will the requested vaccine be used per the recommendations of the Advisory Committee on Immunization Practices (ACIP) and Centers for Disease Control (CDC)? Yes No

Please fax or mail this form to:

Prime Therapeutics LLC
 Clinical Review Department
 2900 Ames Crossing Road Suite 200
 Eagan, MN 55121

TOLL FREE

Phone: 888.274.5158 Fax: 855.212.8110
BCBSFL: 888.271.3183 Fax: 855.212.8110
BCBSNJ: 888.214.1784 Fax: 855.212.8110
BCBSRI: 855.457.0759 Fax: 855.212.8110
CHP: 855.457.0754 Fax: 855.212.8110

CONFIDENTIALITY NOTICE: This communication is intended only for the use of the individual entity to which it is addressed and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.